Female participants who are pregnant, breastfeeding, or may become pregnant, or unwilling to practice birth control during participation in the study or the 6 months following.Female partners of male participants who are unwilling to use at least one form of highly effective contraception starting at least one cycle prior to male patient study drug initiation until 6 months after the last dose of study drug. Male patients, if heterosexually active with partner who is female of childbearing potential, pregnant, or breastfeeding, who are unwilling to agree to barrier contraception for the treatment period and for at least 6 months after the last dose of study drug.Patient shows signs of retinal macular disease, or retinal pigment epithelium abnormality prior to randomization.Meets criteria for a substance use disorder within the past 6 months, with the exception of nicotine use disorder.Diagnosis of a major neurocognitive disorder.A current diagnosis of depression with peripartum onset.History of non-response to electroconvulsive therapy in the current depressive episode.History of non-response to >4 adequate antidepressant trials in the current episode as determined by the Antidepressant Treatment Response Questionnaire (ATRQ).Has a history of schizophrenia or other psychotic disorder, major depressive disorder with psychotic features, or bipolar I or II disorder.A primary psychiatric diagnosis other than MDD as defined by DSM-5. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |